This invention is a low cost, clinically-applicable, single-cell array-based DNA diffusion assay that can be used as a mini-testing platform to assess efficacies of DNA-damaging anti-cancer drugs and radiation dose conditions at point-of-care. 
Technology Overview
The core technique used in this invention is a new single-cell array-based DNA diffusion assay, which is based on a classical halo assay and state-of-the-art microfabrication technique. 
In this method, a small tumor tissue (or blood) derived from a cancer patient is processed to isolate cells which will be suspended in solution and subjected to a genotoxic drug or radiation exposure for certain time. 
Micro patterns formed on a solid substrate are used to trap cells through electrostatic attraction or specific antibody-antigen interaction with receptors expressed on cell surfaces. After embedding arrayed cells inside an agarose gel, DNA damage will be quantified with fast alkaline halo assay, in which DNAs are stained with fluorescence dye.
- Can detect diffusion of damaged DNA fragments and form a halo inside a gel
- High sensitivity
- Higher statistical power
- Can detect double strand DNA breaks, and also non-strand break DNA damages
- Robust, inexpensive and easier to use
- Cancer treatment
- Therapy for individual patients
- License
- Partnering
- Research collaboration
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
Ming Su
Liyuan Ma